FDA Approves ZymoGenetics’ RECOTHROMTM Thrombin, Topical (Recombinant)
Jan 29th 2008Drug InformationBlood
ZymoGenetics, Inc. (NASDAQ:ZGEN) announced that the United States Food and Drug Administration (FDA) has approved RECOTHROMTM Thrombin, topical (Recombinant) for sale. RECOTHROM, previously referred to as recombinant thrombin (rThrombin), is the first and only recombinant, plasma-free thrombin approved for use as a topical hemostat.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
